Results 121 to 130 of about 53,301 (333)

Pitolisant Inhibits Alcohol Drinking and Improves Withdrawal Negative Affect Through Lateral Habenula Histaminergic Signaling in Mice. [PDF]

CNS Neurosci Ther
Pitolisant, an FDA‐approved H3R antagonist, counteracts the rewarding and sedative effects of ethanol, reduces alcohol intake, and alleviates the negative affect during withdrawal. This might occur via the antagonism of presynaptic autoreceptors and heteroreceptors H3Rs in the lateral habenula, thereby activating the H2R/p‐CREB/BDNF signaling and ...
Zhao Y, Fu Y, Liu T, Yang Z, Yang Z, Chen B, Zhou L, Yang J, Chen D, Han X, Tang Y, Ye JH, Miao CY, Fu R.   +13 more
europepmc   +2 more sources

Thymoxyethyldiethylamine as an Antagonist of Histamine and of Anaphylactic Reactions [PDF]

, 1940
Sol Roy Rosenthal, Mary Louise Brown
openalex   +1 more source

Alterations in histamine responses between juvenile and adult urinary bladder urothelium, lamina propria and detrusor tissues [PDF]

, 2020
Chess-Williams, Russ, Moro, Christian, Stromberga, Zane   +2 more
core   +1 more source

Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial

BJU International, Volume 135, Issue 4, Page 638-647, April 2025.
Objectives To evaluate the effect of intravesical alkalinised lidocaine as an anaesthetic treatment on procedural pain during intradetrusor onabotulinumtoxinA (BTX‐A) injections for overactive bladder. Patients and Methods This single‐centre, randomised, double‐blind, placebo‐controlled two period crossover trial was conducted on women scheduled for ...
Meryam El Issaoui, Marlene Elmelund, Niels Klarskov   +2 more
wiley   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Effects of intraduodenally applied bile salts on pancreatic secretion [PDF]

, 1993
Lehnert, Peter, Riepl, Rudolf L.
core   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Comparing the Safety and Efficacy of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists in the Management of Patients With Peptic Ulcer Disease: A Systematic Review [PDF]

, 2023
Maha Begg, Mawada Tarhuni, Monique N. Fotso, Natalie A Gonzalez, Raghavendra Sanivarapu, Usama Osman, Abishek Latha Kumar, Aishwarya Sadagopan, Anas Mahmoud, Safeera Khan   +9 more
openalex   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

4-(ω-(Alkyloxy)alkyl)-1H-imidazole Derivatives as Histamine H₃Receptor Antagonists/Agonists

, 2004
Galina Meier, Michael Krause, Annette Hüls, Xavier Ligneau, Heinz H. Pertz, Jean‐Michel Arrang, C. Robin Ganellin, Jean‐Charles Schwartz, Walter Schunack, Holger Stark   +9 more
openalex   +1 more source